Peter Jürgen Goebell

A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

Thomas B. Powles, Scott T. Tagawa, Christof Vulsteke, Marine Gross-Goupil et autres

Plain Language SummaryWhat is this summary about?Chemotherapy and immunotherapy are often used to treat advanced urothelial cancer. However, for most people, these treatments may stop working and their cancer may get worse. New and better treatments are needed for this common and …

gb, us, be, fr, kr, it, at, es, cn, de (code pays fourni par la source)

Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT

Peter Jürgen Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald et autres

The combination of two immune checkpoint inhibitors (CPI) or a CPI with a tyrosine kinase inhibitor (TKI) has expanded the therapeutic options for advanced/metastatic renal cell carcinoma (aRCC) beyond TKI monotherapy. In the absence of head-to-head randomized trials comparing these strategies, we …

de (code pays fourni par la source)

Effect of Recipient Variables on Transplant Survival Following Marginal Kidney Donation: Analysis of a Mate Kidney Cohort

Ariadni Androvitsanea, Katharina M. Heller, Hendrik Apel, Frank Kunath et autres

BACKGROUND Transplantation using kidneys from older donors or those with specific risk factors (marginal kidneys) offers improved outcomes compared to remaining on dialysis. Matched-pair analysis potentiates control for confounding donor factors and the impact of recipient characteristics on transplant survival. MATERIAL AND …

de (code pays fourni par la source)

Androgenrezeptor-gerichtete Therapien – klinisch relevante Interaktionen vermeiden

Hans-Peter Lipp, Gunhild v. Amsberg, Axel S. Merseburger, Steffen Rausch et autres

Abstract: Pharmacotherapy of older patients requires special attention to drug interactions, based on an increase in morbidity and elevated need for polypharmacy. Especially for drugs with a narrow therapeutic index, interactions may require dose adjustments, discontinuation or switching of co-medication. These interactions …

de (code pays fourni par la source)

PSA im Extrembereich – Ausdruck einer infausten Prognose?

Christian Dirscherl, Thomas H. Ebert, Bernd J. Schmitz‐Dräger, Peter Jürgen Goebell

BACKGROUND: Extremely high baseline prostate-specific antigen (bPSA) values in the range of 100 to ≥ 1000 ng/ml prior to the start of systemic therapy pose a challenge, as they can lead to the impression of a very unfavorable prognosis. OBJECTIVE: We investigated …

de (code pays fourni par la source)

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Lia Bergmann, Laurence K. Albiges, Marit Ahrens, Marine Gross‐Goupil et autres

BACKGROUND: Non-clear cell renal cell cancers (nccRCCs) are a heterogeneous group of more than 20 different entities, but are rarely included in large, randomized trials. Tyrosine kinase inhibitors with or without immune checkpoint inhibition are considered as a standard of care (SOC), …

de, fr, gb, es, be, nl, cz (code pays fourni par la source)

Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK

Peter Jürgen Goebell, Stephanie Chen, Jay K. Jhaveri

AIM: To characterize contemporary global real-world metastatic hormone-sensitive prostate cancer (mHSPC) treatment, guideline concordance, trends, and potential trend drivers. MATERIALS AND METHODS: Retrospective data from the Ipsos Global Oncology Monitor database for the United States, Germany, France, Spain, Italy, and the United …

de, us (code pays fourni par la source)

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial

Thomas B. Powles, Scott T. Tagawa, Christof Vulsteke, Marine Gross‐Goupil et autres

gb, us, be, fr, kr, it, at, de, es, cn (code pays fourni par la source)

Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer.

Boris Alexander Hadaschik, Gunhild v. Amsberg, Ken Herrmann, Axel S. Merseburger et autres

TPS274 Background: Prostate cancer remains the most common malignancy among men and the fifth leading cause of cancer-related mortality globally. Over the past 15 years, advances in imaging techniques and therapeutic options have significantly transformed the management of recurrent, advanced, and metastatic …

de (code pays fourni par la source)

Real-world effectiveness and safety of avelumab first-line maintenance (1LM) treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Second interim analysis of the AVENUE study.

Peter Jürgen Goebell, Alexander Valerievich Sultanbaev, Anna Leena Brachtel, Áurea Molina et autres

706 Background: Avelumab 1LM is standard of care for patients with la/mUC without disease progression after 1L platinum-based chemotherapy (PBC) based on results from the JAVELIN Bladder 100 phase 3 trial. The AVENUE study is evaluating the effectiveness and safety of avelumab …

de, ru, es, ch, us (code pays fourni par la source)

LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis

Petros Grivas, Thomas B. Powles, Christof Vulsteke, M. Gross Goupil et autres

us, gb, be, fr, kr, it, at, de, es, cn (code pays fourni par la source)

Real‐world use of androgen‐deprivation therapy intensification for metastatic hormone‐sensitive prostate cancer: a systematic review

Amit D. Raval, Stephanie Y Chen, Natasha Littleton, Niculae Constantinovici et autres

OBJECTIVE: To conduct a systematic literature review of real-world data (RWD) studies to summarise treatment patterns among men with metastatic hormone-sensitive prostate cancer (mHSPC). While androgen-deprivation therapy (ADT) is a primary treatment strategy for mHSPC, ADT intensification with androgen receptor pathway inhibitors …

us, ch, de (code pays fourni par la source)